Home > Cardiology > ISTH 2020 > What’s New in Anticoagulation > Higher thrombotic risk in NSCLC patient with ALK rearrangement

Higher thrombotic risk in NSCLC patient with ALK rearrangement

Presented By
Dr Hanny Al-Samkari, Massachusetts General Hospital, USA
ISTH 2020
  A retrospective observational study showed that anaplastic lymphoma kinase gene (ALK) rearrangement in lung cancer patients is associated with a 3 to 4 times elevated thrombotic risk compared with ALK-negative lung cancer patients [1]. Chromosomal translocations involving ALK are rare oncogenic events found in 3-5% of non-small-cell lung cancers (NSCLC). Prior studies have shown that ALK rearrangement in NSCLC patients might confer an elevated risk for cancer-associated venous thromboembolism (VTE). Dr Hanny Al-Samkari (Massachusetts General Hospital, USA) and colleagues compared the risk for VTE and arterial thrombosis of 400 NSCLC patients with ALK rearrangement with 800 NSCLC patients without ALK rearrangement who were treated between 2009 and 2019. They performed multivariable time-to-event analysis to assess the risk of first venous or arterial thrombosis in ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on